Huntingtin-protein interactions and the pathogenesis of Huntington's disease

Trends in Genetics

Volumn 20, Issue 3, 2004, Pages 146-154

  Li, Shi Hua ^a   Li, Xiao Jiang ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALMODULIN; CYSTATHIONINE BETA SYNTHASE; GLUTATHIONE TRANSFERASE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; HUNTINGTIN; INOSITOL 1,4,5 TRISPHOSPHATE RECEPTOR; POLYGLUTAMINE; TATA BINDING PROTEIN; TATA BINDING PROTEIN ASSOCIATED FACTOR; TRANSCRIPTION FACTOR; UBIQUITIN CONJUGATING ENZYME;

DEGENERATIVE DISEASE; HUMAN; HUNTINGTON CHOREA; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RECEPTOR BINDING; REVIEW; TRANSCRIPTION INITIATION;

EID: 1242338856     PISSN: 01689525     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tig.2004.01.008     Document Type: Review

References (88)

1. Zoghbi H.Y., Orr H.T. Glutamine repeats and neurodegeneration. Annu. Rev. Neurosci. 23:2000;217-247.
2. Nakamura K., et al. SCA17, a novel autosomal dominant cerebellar ataxia caused by an expanded polyglutamine in TATA-binding protein. Hum. Mol. Genet. 10:2001;1441-1448.
3. Vonsattel J.P., et al. Neuropathological classification of Huntington's disease. J. Neuropathol. Exp. Neurol. 44:1985;559-577.
4. Harjes P., Wanker E.E. The hunt for huntingtin function: interaction partners tell many different stories. Trends Biochem. Sci. 28:2003;425-433.
5. Takano, H. and Gusella, J.F. (2002) The predominantly HEAT-like motif structure of huntingtin and its association and coincident nuclear entry with dorsal, an NF-kB/Rel/dorsal family transcription factor. BMC Neurosci. 3, 15 ( www.biomedcentral.com/1471-2202/3/15 ).
6. Neuwald A.F., Hirano T. HEAT repeats associated with condensins, cohesins, and other complexes involved in chromosome-related functions. Genome Res. 10:2000;1445-1452.
7. DiFiglia M., et al. Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons. Neuron. 14:1995;1075-1081.
8. Sharp A.H., et al. Widespread expression of Huntington's disease gene (IT15) protein product. Neuron. 14:1995;1065-1074.
9. Gutekunst C.A., et al. The cellular and subcellular localization of huntingtin-associated protein 1 (HAP1): comparison with huntingtin in rat and human. J. Neurosci. 18:1998;7674-7686.
10. Cattaneo E., et al. Loss of normal huntingtin function: new developments in Huntington's disease research. Trends Neurosci. 24:2001;182-188.
11. Dragatsis I., et al. Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice. Nat. Genet. 26:2000;300-306.
12. Davies S.W., et al. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell. 90:1997;537-548.
13. Reddy P.H., et al. Behavioural abnormalities and selective neuronal loss in HD transgenic mice expressing mutated full-length HD cDNA. Nat. Genet. 20:1998;198-202.
14. Schilling G., et al. Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Hum. Mol. Genet. 8:1999;397-407.
15. Hodgson J.G., et al. A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron. 23:1999;181-192.
16. Hackam A.S., et al. The influence of huntingtin protein size on nuclear localization and cellular toxicity. J. Cell Biol. 141:1998;1097-1105.
17. DiFiglia M., et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science. 277:1997;1990-1993.
18. Kim Y.J., et al. Caspase 3-cleaved N-terminal fragments of wild-type and mutant huntingtin are present in normal and Huntington's disease brains, associate with membranes, and undergo calpain-dependent proteolysis. Proc. Natl. Acad. Sci. U. S. A. 98:2001;12784-12789.
19. Gafni J., Ellerby L.M. Calpain activation in Huntington's disease. J. Neurosci. 22:2002;4842-4849.
20. Wellington C.L., et al. Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington's disease. J. Neurosci. 22:2002;7862-7872.
21. Lunkes A., et al. Proteases acting on mutant huntingtin generate cleaved products that differentially build up cytoplasmic and nuclear inclusions. Mol. Cell. 10:2002;259-269.
22. Zhou H., et al. Huntingtin forms toxic N-terminal fragment complexes that are promoted by the age-dependent decrease in proteasome activity. J. Cell Biol. 163:2003;109-118.
23. Mantamadiotis T., et al. Disruption of CREB function in brain leads to neurodegeneration. Nat. Genet. 31:2002;47-54.
24. Myers S.J., et al. Genetic regulation of glutamate receptor ion channels. Annu. Rev. Pharmacol. Toxicol. 39:1999;221-241.
25. Luthi-Carter R., et al. Dysregulation of gene expression in the R6/2 model of polyglutamine disease: parallel changes in muscle and brain. Hum. Mol. Genet. 11:2002;1911-1926.
26. Gerber H.P., et al. Transcriptional activation modulated by homopolymeric glutamine and proline stretches. Science. 263:1994;808-811.
27. McCampbell A., et al. CREB-binding protein sequestration by expanded polyglutamine. Hum. Mol. Genet. 9:2000;2197-2202.
28. Chai Y., et al. The role of protein composition in specifying nuclear inclusion formation in polyglutamine disease. J. Biol. Chem. 276:2001;44889-44897.
29. Nucifora F.C. Jr, et al. Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Science. 291:2001;2423-2428.
30. Steffan J.S., et al. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature. 413:2001;739-743.
31. Hockly E., et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc. Natl. Acad. Sci. U. S. A. 100:2003;2041-2046.
32. Ferrante R.J., et al. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J. Neurosci. 23:2003;9418-9427.
33. Ryu H., et al. Histone deacetylase inhibitors prevent oxidative neuronal death independent of expanded polyglutamine repeats via an Sp1-dependent pathway. Proc. Natl. Acad. Sci. U. S. A. 100:2003;4281-4286.
34. Perutz M.F., et al. Glutamine repeats as polar zippers: their possible role in inherited neurodegenerative diseases. Proc. Natl. Acad. Sci. U. S. A. 91:1994;5355-5358.
35. Huang C.C., et al. Amyloid formation by mutant huntingtin: threshold, progressivity and recruitment of normal polyglutamine proteins. Somat. Cell Mol. Genet. 24:1998;217-233.
36. Perez M.K., et al. Recruitment and the role of nuclear localization in polyglutamine-mediated aggregation. J. Cell Biol. 143:1998;1457-1470.
37. II130, interfering with CREB-dependent transcription. Nat. Genet. 26:2000;29-36.
38. Yu Z.X., et al. Huntingtin inclusions do not deplete polyglutamine- containing transcription factors in HD mice. Hum. Mol. Genet. 11:2002;905-914.
39. Kita H., et al. Modulation of polyglutamine-induced cell death by genes identified by expression profiling. Hum. Mol. Genet. 11:2002;2279-2287.
40. Sipione S., et al. Early transcriptional profiles in huntingtin- inducible striatal cells by microarray analyses. Hum. Mol. Genet. 11:2002;1953-1965.
41. Li S.H., et al. Interaction of Huntington disease protein with transcriptional activator Sp1. Mol. Cell. Biol. 22:2002;1277-1287.
42. Dunah A.W., et al. Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. Science. 296:2002;2238-2243.
43. Cha J.H. Transcriptional dysregulation in Huntington's disease. Trends Neurosci. 23:2000;387-392.
44. Sugars K.L., Rubinsztein D.C. Transcriptional abnormalities in Huntington disease. Trends Genet. 19:2003;233-238.
45. Zuccato C., et al. Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nat. Genet. 35:2003;76-83.
46. Glued subunit of dynactin. Hum. Mol. Genet. 6:1997;2205-2212.
47. Glued. J. Neurosci. 18:1998;1261-1269.
48. Li Y., et al. Huntingtin-associated protein 1 interacts with hepatocyte growth factor-regulated tyrosine kinase substrate and functions in endosomal trafficking. J. Biol. Chem. 277:2002;28212-28221.
49. Tang T.S., et al. Huntingtin and huntingtin-associated protein 1 influence neuronal calcium signaling mediated by inositol-(1,4,5) triphosphate receptor type 1. Neuron. 39:2003;227-239.
50. Marcora E., et al. Stimulation of NeuroD activity by huntingtin and huntingtin-associated proteins HAP1 and MLK2. Proc. Natl. Acad. Sci. U. S. A. 100:2003;9578-9583.
51. Block-Galarza J., et al. Fast transport and retrograde movement of huntingtin and HAP 1 in axons. Neuroreport. 8:1997;2247-2251.
52. Chan E.Y., et al. Targeted disruption of Huntingtin-associated protein-1 (Hap1) results in postnatal death due to depressed feeding behavior. Hum. Mol. Genet. 11:2002;945-959.
53. Li S.H., et al. Lack of huntingtin-associated protein-1 causes neuronal death resembling hypothalamic degeneration in Huntington's disease. J. Neurosci. 23:2003;6956-6964.
54. Kalchman M.A., et al. HIP1, a human homologue of S. cerevisiae Sla2p, interacts with membrane-associated huntingtin in the brain. Nat. Genet. 16:1997;44-53.
55. Metzler M., et al. HIP1 functions in clathrin-mediated endocytosis through binding to clathrin and adaptor protein 2. J. Biol. Chem. 276:2001;39271-39276.
56. Waelter S., et al. The huntingtin interacting protein HIP1 is a clathrin and α-adaptin-binding protein involved in receptor-mediated endocytosis. Hum. Mol. Genet. 10:2001;1807-1817.
57. Mishra S.K., et al. Clathrin- and AP-2-binding sites in HIP1 uncover a general assembly role for endocytic accessory proteins. J. Biol. Chem. 276:2001;46230-46236.
58. Metzler M., et al. Disruption of the endocytic protein HIP1 results in neurological deficits and decreased AMPA receptor trafficking. EMBO J. 22:2003;3254-3266.
59. Rao D.S., et al. Altered receptor trafficking in huntingtin interacting protein 1-transformed cells. Cancer Cell. 3:2003;471-482.
60. Hackam A.S., et al. Huntingtin interacting protein 1 induces apoptosis via a novel caspase-dependent death effector domain. J. Biol. Chem. 275:2000;41299-41308.
61. Gervais F.G., et al. Recruitment and activation of caspase-8 by the Huntingtin-interacting protein Hip-1 and a novel partner Hippi. Nat. Cell Biol. 4:2002;95-105.
62. Singaraja R.R., et al. HIP14, a novel ankyrin domain-containing protein, links huntingtin to intracellular trafficking and endocytosis. Hum. Mol. Genet. 11:2002;2815-2828.
63. Modregger J., et al. PACSIN 1 interacts with huntingtin and is absent from synaptic varicosities in presymptomatic Huntington's disease brains. Hum. Mol. Genet. 11:2002;2547-2558.
64. Sittler A., et al. SH3GL3 associates with the Huntingtin exon 1 protein and promotes the formation of polygln-containing protein aggregates. Mol. Cell. 2:1998;427-436.
65. Sun Y., et al. Polyglutamine-expanded huntingtin promotes sensitization of N-methyl-D-aspartate receptors via post-synaptic density 95. J. Biol. Chem. 276:2001;24713-24718.
66. Cepeda C., et al. NMDA receptor function in mouse models of Huntington disease. J. Neurosci. Res. 66:2001;525-539.
67. Zeron M.M., et al. Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease. Neuron. 33:2002;849-860.
68. Li H., et al. Abnormal association of mutant huntingtin with synaptic vesicles inhibits glutamate release. Hum. Mol. Genet. 12:2003;2021-2030.
69. Li H., et al. Ultrastructural localization and progressive formation of neuropil aggregates in Huntington's disease transgenic mice. Hum. Mol. Genet. 8:1999;1227-1236.
70. Li H., et al. Huntingtin aggregate-associated axonal degeneration is an early pathological event in Huntington's disease mice. J. Neurosci. 21:2001;8473-8481.
71. Gutekunst C.A., et al. Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology. J. Neurosci. 19:1999;2522-2534.
72. Liu Y.F., et al. SH3 domain-dependent association of huntingtin with epidermal growth factor receptor signaling complexes. J. Biol. Chem. 272:1997;8121-8124.
73. Busch A., et al. Mutant huntingtin promotes the fibrillogenesis of wild-type huntingtin: a potential mechanism for loss of huntingtin function in Huntington's disease. J. Biol. Chem. 278:2003;41452-41461.
74. Zhang Y., et al. Depletion of wild-type huntingtin in mouse models of neurologic diseases. J. Neurochem. 87:2003;101-106.
75. Q111 knock-in mice. Hum. Mol. Genet. 9:2000;503-513.
76. Holbert S., et al. The Gln-Ala repeat transcriptional activator CA150 interacts with huntingtin: neuropathologic and genetic evidence for a role in Huntington's disease pathogenesis. Proc. Natl. Acad. Sci. U. S. A. 98:2001;1811-1816.
77. Steffan J.S., et al. The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc. Natl. Acad. Sci. U. S. A. 97:2000;6763-6768.
78. Kegel K.B., et al. Huntingtin is present in the nucleus, interacts with the transcriptional corepressor C-terminal binding protein, and represses transcription. J. Biol. Chem. 277:2002;7466-7476.
79. Faber P.W., et al. Huntingtin interacts with a family of WW domain proteins. Hum. Mol. Genet. 7:1998;1463-1474.
80. Boutell J.M., et al. Aberrant interactions of transcriptional repressor proteins with the Huntington's disease gene product, huntingtin. Hum. Mol. Genet. 8:1999;1647-1655.
81. Wanker E.E., et al. HIP-I: a huntingtin interacting protein isolated by the yeast two-hybrid system. Hum. Mol. Genet. 6:1997;487-495.
82. Bao J., et al. Expansion of polyglutamine repeat in huntingtin leads to abnormal protein interactions involving calmodulin. Proc. Natl. Acad. Sci. U. S. A. 93:1996;5037-5042.
83. Holbert S., et al. Cdc42-interacting protein 4 binds to huntingtin: neuropathologic and biological evidence for a role in Huntington's disease. Proc. Natl. Acad. Sci. U. S. A. 100:2003;2712-2717.
84. Boutell J.M., et al. Huntingtin interacts with cystathionine β-synthase. Hum. Mol. Genet. 7:1998;371-378.
85. Burke J.R., et al. Huntingtin and DRPLA proteins selectively interact with the enzyme GAPDH. Nat. Med. 2:1996;347-350.
86. Kalchman M.A., et al. Huntingtin is ubiquitinated and interacts with a specific ubiquitin-conjugating enzyme. J. Biol. Chem. 271:1996;19385-19394.
87. Gunawardena S., et al. Disruption of axonal transport by loss of huntingtin or expression of pathogenic polyQ proteins in Drosophila. Neuron. 40:2003;25-40.
88. Szebenyi G., et al. Neuropathogenic forms of huntingtin and androgen receptor inhibit fast axonal transport. Neuron. 40:2003;41-52.